- The World Health Organization (WHO) warns that cuts to USAID funding for HIV/AIDS programs, initiated by the Trump administration, are causing drug shortages and increasing the risk of drug resistance.
- Millions of people, particularly in sub-Saharan Africa, rely on dolutegravir (DTG), a crucial HIV drug now in short supply. Experts predict a significant rise in drug resistance if shortages continue, jeopardising long-term HIV control.
- The WHO expresses concern about the lack of a readily available, affordable, and equally effective alternative to DTG, especially for vulnerable populations like children and pregnant women.
- The funding cuts have led to clinic closures and treatment interruptions, exacerbating the risk of infections and drug-resistant strains.
- While the US State Department claims that life-saving HIV services are ongoing and under review, there's no confirmation of funding restoration, leaving millions at risk.
IN FULL
